Les Biologistes Indépendants

What Les Biologistes Indépendants does

Les Biologistes Indépendants (LBI) is a French cooperative network of independent medical biology laboratories, founded in 2016 and headquartered in Metz. The network comprises 650-724 laboratory sites covering 80% of French territory, employs approximately 8,000 collaborators including more than 1,000 medical biologists, and serves roughly 80,000 patients per day — equivalent to ~29 million patient visits annually. LBI explicitly positions itself as the largest organized ensemble of independent medical biology laboratories in France, with 100% of member enterprises owned by the practicing biologists themselves, in deliberate opposition to financialized laboratory consolidation.

The network's product surface spans clinical pathology (routine hematology, biochemistry, immunoassay), molecular biology, genetics, and infectious disease screening, including dedicated cancer screening (colorectal, cervical, breast), STI testing, and HPV diagnostics. Its principal technical differentiator is the OuiLab high-throughput sequencing platform at the Laxou technical plateau — a fully automated NGS system built on Illumina sequencing and two Hamilton robots, originally deployed for SARS-CoV-2 genome sequencing and variant identification (in partnership with ID Solutions for RT-PCR variant screening) and now expanding into constitutional genetics and tumor genome sequencing. Supporting specialized capabilities include constitutional genetics at Strasbourg and a non-invasive prenatal screening center near Metz. The network also offers a portfolio of member services: purchasing, insurance, IT, quality management, communications, regulatory watch, HR, and legal support.

LBI's business model is structured around a dual-entity legal architecture: LBI Développement (SAS à capital variable) handles network development and communications, while LBI Coopérative (SA à capital variable) manages purchasing, member databases, and member communications. Revenue derives from fees on medical biology analyses, which are priced under France's regulated Sécurité Sociale nomenclature (NABM) and reimbursed through national health insurance funds. Growth is driven by territorial network expansion through laboratory affiliations and mergers (OuiLab 2021, DIAGNOVIE 2024, UNIBIO-BIOPTIMA-DYNABIO 2025, Croix Blanche and Audolys Biologie 2026) and through capability upgrades in advanced diagnostics. The network holds approximately 20% of the French private medical biology market and is a member of APBM, the federation representing 85% of French private laboratories.

Name

Les Biologistes Indépendants

Legal name

LBI DEVELOPPEMENT SAS à capital variable

Website

https://lesbiologistesindependants.fr

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

Les Biologistes Indépendants is a French cooperative network of 650+ independent medical biology laboratories serving 80,000 patients daily across 80% of French territory. It delivers clinical diagnostics, molecular biology, genetic sequencing, and shared services to member-owned laboratories holding approximately 20% of the French private medical biology market.

Ownership category

akta.pro rank

Headquarters

HQ city

Metz

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Medical Analysis Services: The network operates medical biology laboratories providing clinical pathology, molecular biology, genetics, and screening tests to patients and healthcare professionals (prescribers). Revenue is generated through medical analysis fees charged to patients, health insurance funds, and national health systems.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels8 records

Core offering

Les Biologistes Indépendants operates a national network of independent medical biology laboratories in France delivering clinical pathology, molecular biology, genetics, and screening tests to patients and prescribing healthcare professionals. It also functions as a cooperative platform providing shared services — purchasing, insurance, IT, communications, quality, HR, legal support — to its member laboratories that retain independent ownership. The network offers specialized diagnostic capabilities including a high-throughput next-generation sequencing (NGS) platform at the OuiLab technical plateau in Laxou.

Product overview

Les Biologistes Indépendants operates as a unified platform of independent medical analysis laboratories, offering a comprehensive portfolio of diagnostic services. The core offering consists of a network of 650+ proximity laboratories serving patients across 80% of French territory. Key specialized services include the OuiLab technical platform featuring fully automated next-generation sequencing (NGS) capabilities, and specialized testing for cancer screening (colorectal, cervical, breast), infectious diseases (STIs, COVID-19), and genetic analyses. The network provides laboratory services spanning routine blood tests, molecular biology, genetic sequencing, and preventive health screenings.

Differentiator

Problem solved

Functional benefit

Products and services

• Réseau de Laboratoires d'Analyses Médicales (Network of Medical Analysis Laboratories)

Named customers2 records

Segments2 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Eleven partnerships are on record, tiered core and minor.

• LBI Développement (SAS)coreOthersLBI Développement is a SAS with variable capital, headquartered at 11 avenue Leclerc de Hauteclocque, Metz. It serves as the development entity of the Les Biologistes Indépendants network, acting as the legal publisher responsible for treatment of the website and network communications. The Présidente du Conseil d'Administration is Dominique LUNTE.
• LBI Coopérative (SA)coreOthersLBI Coopérative is a société anonyme à capital variable, the cooperative entity of the network, responsible for data processing related to member databases, purchasing management, and member communications. The Président du Conseil d'Administration is Christian LAENG.
• ID SolutionscoreTechnology or IntegrationPartnership with Montpellier-based company ID Solutions enabled LBI laboratories to implement RT-PCR variant screening tests identifying English, South African, and Brazilian COVID-19 variants. This technology was deployed across multiple technical platforms to support regional epidemiological surveillance.
• EspaceBiocoreStrategic or Co-development PartnerEspaceBio, a founding member of the LBI network, hosts the OuiLab high-throughput sequencing platform at Laxou, which was developed for the entire LBI group. EspaceBio has played a leading role in COVID testing, variant detection, and SARS-CoV-2 genome sequencing, and partnered with ID Solutions for routine variant screening.
• OuiLab Group (BioAllan, Bio67, EspaceBio)coreStrategic or Co-development PartnerOuiLab was created by the merger of three laboratory groups from the Grand Est region: BioAllan, Bio67, and EspaceBio. The group serves as a member of the LBI network, operating 130 sites and establishing a fully automated next-generation sequencing platform at Laxou, constitutional genetics at Strasbourg, and a non-invasive screening antenn near Metz.
• Laboratoires de Proximité Associés (LPA)coreStrategic or Co-development PartnerLPA, with 12 sites and over 200 employees, obtained the AFNOR 'Confirmé' RSE label in April 2023. Under the leadership of Étienne Lombardot, LPA created the Ekorse application to support SMEs and ETIs in their RSE approach. LBI leverages LPA's expertise to formalize and promote RSE actions within its network.
• UNIBIO, BIOPTIMA, DYNABIO (merged)coreStrategic or Co-development PartnerThree independent laboratory groups — UNIBIO, BIOPTIMA, and DYNABIO — merged under the LBI network to preserve independence against large financial groups. The fusion includes competency and resource pooling, shared governance between associate biologists, no job cuts, and ambitions in preventive and specialized biology, supported by the LBI network.
• Groupe B2A (Analysis, Biolia, Biorhin)coreStrategic or Co-development PartnerThe B2A group, a union of Analysis, Biolia, and Biorhin laboratories in the Grand Est region, is a member of the LBI network and was cited in a study by Les Echos Etudes on how the health crisis accelerates mutations in medical biology.
• Laboratoire de la Croix Blanche, Audolys BiologiecoreStrategic or Co-development PartnerTwo new laboratory entities joined the LBI network: Laboratoire de la Croix Blanche and Audolys Biologie. Their testimonies in Spectra Diagnostic N°44 highlight the concrete benefits of LBI membership — commercial support, legal guidance, supplier negotiation, insurance, regulatory watch, and shared tools and resources — while maintaining their autonomy.
• Association pour le Progrès de la Biologie Médicale (APBM)coreStrategic or Co-development PartnerLBI is a member of APBM, which federates 85% of private French laboratories. APBM played a key role during the COVID-19 pandemic, representing the interests of private medical biology laboratories in press conferences, government discussions, and public health efforts.
• Agence Régionale de Santé Grand EstminorOthersLBI member laboratory EspaceBio signed a convention with the ARS Grand Est to perform SARS-CoV-2 genome sequencing, participating in national epidemiological surveillance and representing the private biology sector in public health monitoring.

Scale indicators5 records

Recent moves10 records

Expansion highlights6 records

Direct peers

• Inovie: One of the largest private medical biology laboratory networks in France, operating a multi-site platform directly comparable to LBI in service offering (clinical pathology, molecular biology, genetics) and French geography, and cited alongside LBI as a major consolidator of independent labs.
• Biogroup: Major French network of medical biology laboratories built through consolidation of independent labs, directly competing with LBI for affiliation of biologists and offering the same routine and specialty diagnostic testing menu across France.

Broad incumbents

• Synlab: Europe-wide medical diagnostics provider with significant presence in French medical biology; competes with LBI for affiliations and runs the same routine-plus-specialty testing model, but at much larger EU-wide scale.
• Cerba HealthCare: French-headquartered specialty and routine medical biology operator with strong specialty diagnostics positioning (including genetics and oncology), comparable to LBI's NGS push while operating a broader multi-country footprint.
• Unilabs: European diagnostics provider active in France offering routine and specialty medical biology tests; competes with LBI's network on routine analyses and on specialty services such as genetics and oncology testing.
• Eurofins: Global testing services group with significant clinical diagnostics and genetic testing operations across Europe; overlaps with LBI on clinical biology and NGS services, but Eurofins spans multiple non-medical testing verticals.

Emerging players

• Life Genomics: European clinical genetics / NGS-focused laboratory provider; comparable to LBI's OuiLab NGS platform in oncology genetics and constitutional genetics services, though smaller and more narrowly focused.

Regional players

• Laborizon: French regional medical biology operator with multi-site presence comparable to LBI's local laboratory networks (e.g., Grand Est), competing for prescriber relationships and routine test volume in overlapping French regions.

Others

• Mayoly Spindler (Diagnostics): French diagnostics-adjacent company; relevant as a domestic French healthcare ecosystem participant rather than a direct laboratory-network competitor, useful for benchmarking partnership and supplier dynamics within the French market.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/lesbiologistesindependants/?ref=bookmarks
• LinkedInlinkedin.com/company/lesbiologistesind%C3%A9pendants/mycompany/?viewAsMember=true
• Instagraminstagram.com/lesbiologistesindependants
• Xx.com/Reseau_LBI

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Les Biologistes Indépendants